Clinical trials recruiting for Neuroendocrine Tumors

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• 18F-DOPA II - PET Imaging Optimization
  NCT04706910 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
  NCT06505824 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
  NCT06805825 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
  NCT03412877 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 2 locations
• Agnostic Therapy in Rare Solid Tumors
  NCT06638931 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
  NCT05000294 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
  NCT06345079 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Clinical Application of the J-PET Scanner Prototype
  NCT06242119 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
  NCT04104529 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
  NCT06263088 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
  NCT05918302 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
  NCT06472388 · Phase: Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• F-Tryptophan PET/CT in Human Cancers
  NCT05556473 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  NCT04119024 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Iconographic Registry of Pancreatobiliary Endoscopy Procedures
  NCT06344507 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Integrated Cancer Repository for Cancer Research
  NCT02012699 · Phase: Not specified · Ages: 19 Years to 110 Years · Sex: All (male and female) · 84 locations
• Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
  NCT03206060 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
  NCT04074135 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 1 location
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 204 locations
• Sapu003 in Advanced mTOR-sensitive Solid Tumors
  NCT07369505 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Spanish Series of Patients Treated With the Radionuclide Lutetium177
  NCT04949282 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · 20 locations
• Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
  NCT06735560 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
  NCT05477576 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
  NCT07165132 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• TARGETed Therapy Drug MONITOring in DIGestive Oncology
  NCT05443087 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 29 locations

Related conditions

Trials recruiting for Neuroendocrine Tumors often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Neuroendocrine Tumors trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.